RestructuringAug 11, 2026, 08:37 AM
PDS Biotech Refocuses on PDS0301; Seeks PDS0101 Partnerships
AI Summary
PDS Biotechnology Corporation announced a strategic refocus, prioritizing the advancement of its tumor-targeted immunocytokine PDS0301 for metastatic colorectal cancer (mCRC) and other solid tumors. The company will cease internal investment in the PDS0101 Phase 3 VERSATILE-003 trial and seek strategic partnerships for its continued development. This decision follows a comprehensive review of its development portfolio and capital allocation priorities, aiming to maximize long-term shareholder value. PDS0301 showed encouraging Phase 2 data with a 71% objective response rate and 80% 24-month survival rate in mCRC patients.
Key Highlights
- PDS Biotech announced a strategic refocus, prioritizing PDS0301 development.
- The company will cease internal investment in the PDS0101 Phase 3 VERSATILE-003 trial.
- PDS Biotech intends to pursue strategic partnerships for PDS0101's continued development.
- PDS0301 Phase 2 data in mCRC showed a 71% objective response rate at 6 months.
- PDS0301 Phase 2 data also showed an 80% 24-month survival rate in mCRC patients.
- PDS0301 has been treated in over 380 patients with an encouraging safety profile.
- The company expects to advance PDS0301 through a randomized Phase 2b program over 18-24 months.
- PDS Biotech will announce Q2 2026 financial results on August 13, 2026.
Price Impact
More from PDSB